Want to see EVFM full AI Analyst Report?
Top Page
Evofem Biosciences
(OTC:EVFM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.01
▲(0.00% Upside)
Action:Upgraded
Date:09/24/26
The score is primarily held back by weak financial performance—sharp TTM revenue decline, severe TTM net losses, and a structurally weak balance sheet with negative equity and meaningful debt—despite strong gross margins and improved (but still negative) cash flow. Corporate events are mixed, with manufacturing expansion a positive but costly, restrictive financing a notable risk. Limited technical and valuation data keep those components closer to neutral-to-weak.
Positive Factors
Strong gross margin
A gross margin of about 71% indicates that Phexxi generates substantial value after direct product costs. If maintained, this provides a foundation for covering operating expenses, supporting commercialization investments, and improving earnings potential as revenue scale and manufacturing economics develop.
Negative Factors
Declining revenue
A revenue decline of roughly 23.8% signals weakening recent commercial performance and makes it harder to absorb the company’s operating cost base. Persistent contraction could limit investment capacity, weaken negotiating leverage, and delay the benefits expected from expanded Phexxi production.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong gross margin
A gross margin of about 71% indicates that Phexxi generates substantial value after direct product costs. If maintained, this provides a foundation for covering operating expenses, supporting commercialization investments, and improving earnings potential as revenue scale and manufacturing economics develop.
Read all positive factors
Evofem Biosciences (EVFM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.02M
Dividend YieldN/A
Average Volume (3M)479.42K
Price to Earnings (P/E)―
Beta (1Y)-0.04
Revenue Growth4.49%
EPS Growth-89.40%
CountryUS
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.11
Shares Outstanding132,530,080
10 Day Avg. Volume708,277
30 Day Avg. Volume479,419
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-0.02
Price to Sales (P/S)0.06
P/FCF Ratio-0.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)57.5
Revenue Forecast (FY)$241.13M
Evofem Biosciences Business Overview & Revenue Model
Company Description
Evofem Biosciences, Inc. operates as a biopharmaceutical enterprise dedicated to innovating and bringing to market treatments that address critical underserved areas in women's sexual and reproductive health. Their leading commercial offering is P...
Evofem Biosciences Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.05M | 20.18M | 19.36M | 18.22M | 16.84M | 8.24M |
| Gross Profit | 13.04M | 15.07M | 15.53M | 11.71M | 12.42M | 4.19M |
| EBITDA | -4.27M | 2.06M | -6.92M | -16.07M | -82.08M | -165.78M |
| Net Income | -15.30M | 391.00K | -8.86M | 52.98M | -76.70M | -205.19M |
Balance Sheet | ||||||
| Total Assets | 7.52M | 20.27M | 23.79M | 10.55M | 25.16M | 42.51M |
| Cash, Cash Equivalents and Short-Term Investments | 285.00K | 578.00K | 741.00K | 580.00K | 2.77M | 7.73M |
| Total Debt | 68.50M | 54.55M | 45.97M | 43.37M | 71.13M | 115.68M |
| Total Liabilities | 90.01M | 89.71M | 95.05M | 77.06M | 96.96M | 142.09M |
| Stockholders Equity | -82.49M | -69.44M | -71.26M | -66.51M | -71.80M | -99.58M |
Cash Flow | ||||||
| Free Cash Flow | -477.00K | -2.00M | -3.90M | -8.97M | -70.75M | -149.61M |
| Operating Cash Flow | -472.00K | -1.99M | -3.88M | -8.97M | -70.41M | -146.67M |
| Investing Cash Flow | 52.00K | -62.00K | -569.00K | -4.00K | -341.00K | -2.69M |
| Financing Cash Flow | 14.00K | 1.89M | 4.62M | 4.78M | 61.94M | 90.69M |
Evofem Biosciences Risk Analysis
Evofem Biosciences disclosed 87 risk factors in its most recent earnings report. Evofem Biosciences reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Evofem Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $17.31M | -1.12 | -64.75% | ― | -62.70% | -121.27% | |
44 Neutral | $1.02M | -0.06 | 20.76% | ― | 4.49% | -89.40% | |
43 Neutral | $17.96M | -1.82 | -141.40% | ― | ― | ― | |
43 Neutral | $15.25M | -0.95 | -748.08% | ― | ― | ― |
* Healthcare Sector Average
EVFM
Evofem Biosciences
0.01
0.00
0.00%
PTN
Palatin Technologies
9.58
3.27
51.82%
DARE
Daré Bioscience
0.75
-1.34
-64.11%
LPCN
Lipocine
2.09
-0.72
-25.62%
Evofem Biosciences Corporate Events
Business Operations and StrategyProduct-Related Announcements
Evofem Expands PHEXX Manufacturing Capacity for Global Growth
Positive
Sep 23, 2026
On September 17, 2026, Evofem Biosciences entered into a manufacturing agreement with Zhaoke Ophthalmology Pharmaceutical entities in Hong Kong and Guangzhou to add them as a producer and supplier of PHEXX, its hormone-free contraceptive gel. The ...
Business Operations and StrategyRegulatory Filings and Compliance
Evofem Biosciences Updates Investors via New Presentation
Neutral
Jul 20, 2026
Evofem Biosciences, Inc., a biotechnology company focused on women’s health, periodically shares corporate slide presentations with the investment community at industry and other conferences.The company has posted its current slide deck to t...
Business Operations and StrategyPrivate Placements and Financing
Evofem Biosciences Enters New Subordinated Debt Agreement
Negative
Jul 15, 2026
On July 8, 2026, Evofem Biosciences entered into a subordinated promissory note with HUB Cyber Security, Ltd. for $706,304, carrying 12% annual interest compounded monthly and maturing 11 months from that date. The deal closed the same day, and th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.